Speak directly to the analyst to clarify any post sales queries you may have.
The market of viral vector and plasmid DNA manufacturing encompasses the production of plasmid DNA and viral vectors used for gene delivery to develop gene therapies and genetically modified organisms. Viral vectors are tools that molecular biologists use to produce genetic material in cells. This procedure can be completed inside a living organism (in vivo) or cell culture (ex vivo). Meanwhile, plasmid DNA is a small circular DNA strand that can be used to transfer genetic material similarly. Applications for these products range significantly and include clinical gene therapy for hereditary diseases, genetic vaccines, and cancer treatment strategies. End-users of viral vector and plasmid DNA products include pharmaceutical and biopharmaceutical companies, academic and research institutions, and clinical research organizations. The evolution of the viral vector and plasmid DNA manufacturing market is influenced by the increasing number of gene therapy candidates entering clinical trials, advancement in molecular biology technologies, rising investment in personalized medicine, and the growing prevalence of targeted diseases. The commitment of regulatory agencies to fast-track approvals for emerging therapies also supports market expansion. However, the market faces certain challenges, such as the high manufacturing cost due to complex production methods, regulatory hurdles, concerns regarding the safety and efficacy of gene therapy products, and the need for highly specialized technical expertise. On the other hand, the latest potential opportunities in the market include developments in vector design to reduce immunogenicity, increases in scale-up production processes to meet market demands, and advancements in gene-editing tools such as CRISPR/Cas9. Emerging economies expanding their biotechnological sectors also present significant opportunities for market players.
Regional Insights
The Americas, particularly the United States, remain at the forefront of biopharmaceutical research, including developing and manufacturing viral vectors and plasmid DNA. Recent investments and initiatives, such as launching advanced therapy production facilities and federal funding for gene therapy manufacturing, underscore the region's capacity in this field. Canada also contributes significantly, with its collaborative approach between academia and industry facilitating advanced research and development in this sector. The EU countries have been proactive in fostering a conducive environment for the growth of advanced therapy medicinal products (ATMPs), which include gene therapies employing viral vectors and plasmid DNA. Customer purchasing behavior in Europe is often influenced by the alignment of product offerings to these regulatory incentives and the established healthcare systems supporting innovative treatments. The Middle East, while still developing in this field, is seeing increased interest and investment in biotechnology, leading to a gradual increase in regional capabilities for manufacturing viral vectors and plasmid DNA. On the other hand, Africa presents a diverse picture, with South Africa heading in research capabilities, albeit on a smaller scale than global leaders. In APAC, China's commitment to biotech innovation is evident in its growing presence in the viral vector and plasmid DNA manufacturing landscape, supported by substantial government investments in research infrastructure and favorable policies for biotech companies. The country's fast-growing biotech sector translates to strong consumer demand and aggressive customer purchasing behavior towards local and international partnerships and technologies. India, while an emerging player in this field, is experiencing burgeoning demand due to its large population and increasing focus on healthcare innovation.FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Viral Vector & Plasmid DNA Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Viral Vector & Plasmid DNA Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the Viral Vector & Plasmid DNA Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Advanced BioScience Laboratories, Inc., Akron Biotech, Avid Bioservices, Inc., Batavia Biosciences B.V., BioNTech IMFS GmbH, Biovian Oy, c-LEcta GmbH, Charles River Laboratories International, Inc., Creative Biogene, FILTROX AG, Forge Biologics By Ajinomoto Co., Inc., FUJIFILM Diosynth Biotechnologies Inc., GE HealthCare Technologies, Inc., GeneOne Life Science, Inc., Genezen, Genezen Laboratories, Inc., Kaneka Eurogentec S.A., Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, PerkinElmer Inc., REGENXBIO Inc., Spark Therapeutics, Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., uniQure N.V., and Wuxi AppTec Co., Ltd.Market Segmentation & Coverage
This research report categorizes the Viral Vector & Plasmid DNA Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:- Type
- Plasmid DNA
- Viral Vector
- Adeno-Associated Virus
- Adenovirus
- Lentivirus
- Cell Line
- In-vitro
- In-Vivo
- Transfection
- Stable Transfection
- Transient Transfection
- Indication
- Cancer
- Genetic Disorder
- Infectious Disease
- Workflow
- Downstream Processing
- Fill-finish
- Purification
- Upstream Processing
- Vector Amplification & Expansion
- Vector Recovery/Harvesting
- Downstream Processing
- Application
- Cell Therapy
- Gene Therapy
- Vaccinology
- End User
- Pharmaceutical & Biopharmaceutical Companies
- Research Institutes
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as
- What is the market size and forecast of the Viral Vector & Plasmid DNA Manufacturing Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Viral Vector & Plasmid DNA Manufacturing Market?
- What are the technology trends and regulatory frameworks in the Viral Vector & Plasmid DNA Manufacturing Market?
- What is the market share of the leading vendors in the Viral Vector & Plasmid DNA Manufacturing Market?
- Which modes and strategic moves are suitable for entering the Viral Vector & Plasmid DNA Manufacturing Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
Companies Mentioned
- Advanced BioScience Laboratories, Inc.
- Akron Biotech
- Avid Bioservices, Inc.
- Batavia Biosciences B.V.
- BioNTech IMFS GmbH
- Biovian Oy
- c-LEcta GmbH
- Charles River Laboratories International, Inc.
- Creative Biogene
- FILTROX AG
- Forge Biologics By Ajinomoto Co., Inc.
- FUJIFILM Diosynth Biotechnologies Inc.
- GE HealthCare Technologies, Inc.
- GeneOne Life Science, Inc.
- Genezen
- Genezen Laboratories, Inc.
- Kaneka Eurogentec S.A.
- Lonza Group Ltd.
- Merck KGaA
- Miltenyi Biotec B.V. & Co. KG
- PerkinElmer Inc.
- REGENXBIO Inc.
- Spark Therapeutics, Inc.
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
- uniQure N.V.
- Wuxi AppTec Co., Ltd.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 193 |
Published | March 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 1.5 Billion |
Forecasted Market Value ( USD | $ 7.32 Billion |
Compound Annual Growth Rate | 25.3% |
Regions Covered | Global |
No. of Companies Mentioned | 27 |